-
WATCH: RGX-202 – AFFINITY DUCHENNE Pivotal Program and Functional Data (Webinar Recording)
REGENXBIO recently joined PPMD for a community webinar to provide an update on its AFFINITY […]
-
PPMD Culminates 30th Anniversary with Celebratory “Investing in Every Future” Event
PPMD commemorated its 30th anniversary with the “Investing in Every Future” celebratory event on November […]
-
New technology may inform effective MD gene therapies: Study
A new technology called StitchR effectively restored the production of large muscle proteins dystrophin and […]
-
Positive data reported for REGENXBIO’s AAV8-delivered microdystrophin, RGX-202
CureDuchenne is delighted to share the positive updates from REGENXBIO on their Phase 1/2 open-label […]
-
REGENXBIO Initiates Pivotal Phase of AFFINITY DUCHENNE® Trial of RGX-202 Gene Therapy, Reports Positive Functional Data
REGENXBIO Inc. has announced that the AFFINITY DUCHENNE® open-label trial of RGX-202 has advanced to […]
-
Being mindful of kidney stones while living with DMD
“Kidney stones!” my 13-year-old son, Charlie, exclaimed when I asked him what I should write […]
-
FDA OKs trial to test gene therapy candidate in LGMD children
The U.S. Food and Drug Administration (FDA) has given Atamyo Therapeutics the go-ahead to start […]
-
New discovery enables gene therapy for muscular dystrophies, other disorders
StitchR, a new gene therapy technique, delivers large genes in two parts to treat muscular […]
-
Coping with grief and the day-to-day life of LGMD
People living with a chronic illness, including me, commonly explore how we deal with grief, […]
-
Sarepta stops development of exon 51-skipping therapy for DMD
Despite positive trial data, Sarepta Therapeutics has decided to stop the clinical development of SRP-5051 […]
